Cromwell Holdings LLC Invests $61,000 in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Cromwell Holdings LLC bought a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK) in the fourth quarter, HoldingsChannel reports. The firm bought 4,600 shares of the company’s stock, valued at approximately $61,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ieq Capital LLC lifted its stake in shares of Takeda Pharmaceutical by 86.9% during the 4th quarter. Ieq Capital LLC now owns 21,241 shares of the company’s stock worth $281,000 after acquiring an additional 9,874 shares during the last quarter. Venturi Wealth Management LLC lifted its stake in shares of Takeda Pharmaceutical by 554.7% during the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company’s stock worth $67,000 after acquiring an additional 4,260 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Takeda Pharmaceutical by 50.7% during the 4th quarter. Allworth Financial LP now owns 9,582 shares of the company’s stock worth $124,000 after acquiring an additional 3,222 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Takeda Pharmaceutical by 1.6% during the 4th quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company’s stock worth $29,266,000 after acquiring an additional 35,192 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Takeda Pharmaceutical by 14.2% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 20,275 shares of the company’s stock worth $269,000 after acquiring an additional 2,516 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of TAK stock opened at $13.86 on Friday. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.08. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The firm has a market capitalization of $44.08 billion, a P/E ratio of 34.64, a P/E/G ratio of 0.24 and a beta of 0.51. The stock has a 50 day moving average price of $13.28 and a 200 day moving average price of $13.87.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, sell-side analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.